Results 101 to 110 of about 9,189 (185)

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against multidrug-resistant Klebsiella pneumoniae and Escherichia coli

, 2019
Background: Increasing resistance to broad-spectrum cephalosporin and carbapenem in Enterobacteriaceae makes it challenging to select appropriate antibiotics. There are limited treatment options for these pathogens.
이승철
core  

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales

, 2021
In vitro data support the use of combination of aztreonam (ATM) with ceftazidime-avibactam (CAZ-AVI), but clinical studies are lacking. The aim of our study was to compare the outcome of patients with bloodstream infections (BSIs) due to MBLs-producing ...
Tiseo, Giusy, Barnini, Simona, Menichetti, Francesco, Giordano, Cesira, Galfo, Valentina, Daikos, George L, Leonildi, Alessandro, Ghiadoni, Lorenzo, Farcomeni, Alessio, Bassoulis, Dimitrios, Falcone, Marco, Tagliaferri, Enrico, Sani, Spartaco   +12 more
core   +1 more source

In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae

Antimicrobial Resistance and Infection Control, 2018
Background In recent years, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) infections has increased rapidly. Since the CRE strain is usually resistant to most of antimicrobial agents, patients with this infection are often accompanied by ...
Wenxia Zhang, Yan Guo, Jiayin Li, Yiyuan Zhang, Yang Yang, Dong Dong, Demei Zhu, Ping He, Fupin Hu   +8 more
doaj   +1 more source

DataSheet1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx

, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384), Shanshan Long (1783180), Hao Zhou (136535), Jie Zhang (64655), Dan Li (106345), Fan Fei (1368924), Hua Yu (138267)   +6 more
core   +1 more source

Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales. [PDF]

J Clin Microbiol
ABSTRACT The emergence of metallo-β-lactamase (MBL)-producing Enterobacterales presents unique clinical treatment challenges. Recently developed β-lactam/ β-lactamase inhibitor combination agents, while effective against other carbapenemase-producing organisms, are notably ineffective against MBL ...
Lemon JK, Jankowsi-Romano C, Duong S, Juretschko S, Streva VA.   +4 more
europepmc   +3 more sources

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Infection and Drug Resistance, 2023
Junyang Kuai,1 Yawei Zhang,1 Binghuai Lu,2 Hongbin Chen,1 Yulin Zhang,2 Henan Li,1 Yuanyuan Wang,3 Qi Wang,1 Hui Wang,1 Xiaojuan Wang1 1Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of China ...
Kuai J, Zhang Y, Lu B, Chen H, Zhang Y, Li H, Wang Y, Wang Q, Wang H, Wang X   +9 more
doaj  

Presentation_1_Omic insights into various ceftazidime-avibactam-resistant Klebsiella pneumoniae isolates from two southern Italian regions.pptx

, 2023
Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria.
Nadia Marascio (3819316), Maria Lina Mezzatesta (6178598), Angela Quirino (3413834), Giuseppe G. M. Scarlata (14330373), Grete F. Privitera (14330370), Giovanni Matera (6114287), Dalida A. Bivona (14330364), Nicolò Musso (6101027), Stefania Stefani (188822), Carlo Torti (237805), Claudia Cicino (14330367), Dafne Bongiorno (14330361), Alessandro Russo (43423), Enrico M. Trecarichi (10017149)   +13 more
core   +1 more source

Evaluation of the in vitro efficacy of antimicrobials against Enterobacterales with multiple carbapenemase enzymes

Iranian Journal of Microbiology
Background and Objectives: High-dose of carbapenems and combination therapies with new β-lactam/β-lactamase inhibitors and polymyxin B/tigecycline have been considered for treatment of carbapenem resistant Enterobacterales infection.
Reena Rajan, Gopinathan Sasikala
doaj   +1 more source

Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.

, 2020
BACKGROUND: MBL-producing strains of Enterobacteriaceae are a major public health concern. We sought to define optimal combination regimens of ceftazidime/avibactam with aztreonam in a hollow-fibre infection model (HFIM) of MBL-producing strains of ...
Boissonneault, Katie Rose, Lodise, Thomas P, Bonomo, Robert A, Smith, Nicolas M, Holden, Patricia N, Zhou, Jieqiang, Chambers, Henry F, Bulitta, Jurgen B, Tsuji, Brian T, Fowler, Vance G Jr, O'Donnell, J Nicholas, Eakin, Ann E, Tao, Xun   +12 more
core   +1 more source